| Symbol | MREO |
|---|---|
| Name | MEREO BIOPHARMA GROUP PLC |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 4TH FLOOR,ONE CAVENDISH PLACE, LONDON, W1G 0QF, United Kingdom |
| Telephone | +44 333 - 023-7300 |
| Fax | — |
| — | |
| Website | https://www.mereobiopharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001719714 |
| Description | Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases. Its lead oncology product candidate is etigilimab, for patients with advanced solid tumors. Some of the other products in the pipeline are setrusumab, alvelestat, leflutrozole, navicixizumab, and acumapimod. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - Mereo BioPharma Group plc <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0000935836-26-000413 <b>Size:</b> 16 KB
Read moreMereo Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights
Read more(10% Negative) MEREO BIOPHARMA GROUP PLC (MREO) Reports Q3 2026 Financial Results
Read moreMereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights
Read moreMereo BioPharma Announces Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)
Read more(70% Positive) MEREO BIOPHARMA GROUP PLC (MREO) Announces Enrollment Update for agreement Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment
Read moreMereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)
Read moreSentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)
Read moreNew Form SCHEDULE 13G/A - Mereo BioPharma Group plc <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0000935836-26-000265 <b>Size:</b> 16 KB
Read moreNew Form SCHEDULE 13G - Mereo BioPharma Group plc <b>Filed:</b> 2026-05-14 <b>AccNo:</b> 0000070858-26-000293 <b>Size:</b> 171 KB
Read more